modified interleukin-2 DF6215

A modified and recombinant form of the human endogenous cytokine interleukin-2 (IL-2), with potential immunostimulating and antineoplastic activities. Upon administration, modified IL-2 DF6215 targets and binds to IL-2 receptor (IL-2R) expressed on CD8+ T effector cells and activates IL-2R-mediated signaling. This enhances cytotoxic T lymphocytes (CTLs)-mediated cytotoxic immune responses against tumor cells.